Press Enter to search · Esc to close
GLP-1s deliver durable fat loss and metabolic wins — but a maturing evidence base is also flagging ocular signals and structural changes worth knowing before you pin or pass.
A 2026 systematic review reframes the pre-anesthesia question for semaglutide users — less about pausing the drug, more about clearing the stomach and checking it with ultrasound.
New meta-analyses suggest the metabolic-drug story is moving past the scale — toward measurable inflammation reduction and stacked cardiorenal protection. Here's what that actually changes for a 40-year-old.
A once-daily oral GLP-1, fresh data linking the class to lower lumbar disease risk, and a network meta-analysis hinting at a nuanced colorectal cancer question. Here's what the moderate evidence actually says.
Semaglutide reshaped the conversation around obesity. The next round of data — from skeletal muscle to intracranial pressure to oral small molecules — is reshaping what comes next.
A new randomized trial suggests a year of structured exercise after weight loss boosts the body's own appetite-quieting GLP-1 — something the injectable drugs don't appear to do. Here's what that means for anyone serious about keeping the weight off.
A new peer-reviewed review argues the panic over muscle loss with weight-loss drugs may be missing the point. The real question is whether your muscle still works — not what the scale partitions.
A network meta-analysis finally ranks the incretin heavyweights head-to-head, while a novel once-weekly peptide files its first big numbers. Here's what the data actually shows.
A landmark phase 3 trial puts the dual-receptor agonist on the map for adolescents with type 2 diabetes — and new mechanistic work suggests its effects reach all the way down to the mitochondrion.
Semaglutide's clinical footprint is widening fast — new data hint at off-target wins, real-world rescues, and a sharpening list of who should pause before the pen.